Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Non-metastatic NSCLC and other thoracic malignancies

1782MO - Health-related quality of life (HRQoL) in KEYNOTE-604: Pembrolizumab (pembro) or placebo added to etoposide and platinum (EP) as first-line therapy for ES-SCLC

Date

18 Sep 2020

Session

Mini Oral - Non-metastatic NSCLC and other thoracic malignancies

Presenters

Hye Ryun Kim

Citation

Annals of Oncology (2020) 31 (suppl_4): S974-S987. 10.1016/annonc/annonc290

Authors

H.R. Kim1, M.M. Awad2, A. Navarro3, M. Gottfried4, S. Peters5, T. Csőszi6, P.K. Cheema7, D. Rodriguez-Abreu8, M. Wollner9, J.C. Yang10, J. Mazieres11, F.J. Orlandi12, A. Luft13, M. Gümüş14, T. Kato15, G.P. Kalemkerian16, Y. Luo17, M.L. Santorelli17, M.C. Pietanza17, C.M. Rudin18

Author affiliations

  • 1 Medical Oncology, Yonsei Cancer Center, Division of Medical Oncology, Yonsei University College of Medicine, 120-752 - Seoul/KR
  • 2 Medical Oncology, Dana Farber Cancer Institute, 02215 - Boston/US
  • 3 Medical Oncology, Vall d’Hebron University Hospital, 08035 - Barcelona/ES
  • 4 Oncology, Meir Medical Center, 4428164 - Kfar Saba/IL
  • 5 Multidisciplinary Oncology Center, Lausanne University Hospital, 1011 - Lausanne/CH
  • 6 Oncology, Hetenyi G Korhaz Onkologiai Kozpont, Szolnok/HU
  • 7 Medical Oncology, William Osler Health System, University of Toronto, Brampton/CA
  • 8 Medical Oncology, Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria/ES
  • 9 Oncology, Rambam HealthCare Campus, 30196 - Haifa/IL
  • 10 Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, 100 - Taipei/TW
  • 11 Thoracic Oncology, Centre Hospitalier Universitaire de Toulouse, Université Paul Sabatier, 31059 - Toulouse/FR
  • 12 Oncology, Oncología-Health and Care, Santiago/CL
  • 13 Oncology, Leningrad Regional Clinical Hospital, St. Petersburg/RU
  • 14 Oncology, Istanbul Medeniyet University Hospital, 81450 - Istanbul/TR
  • 15 Respiratory Medicine, Kanagawa Cancer Center, 241-8515 - Yokohama/JP
  • 16 Internal Medicine, University of Michigan, 48109 - Ann Arbor/US
  • 17 Oncology, Merck & Co., Inc., 07033 - Kenilworth/US
  • 18 Medicine, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
More

Resources

Login to access the resources on OncologyPRO.

Abstract 1782MO

Background

In the randomized, double-blind, phase 3 KEYNOTE-604 study (NCT03066778), pembro-EP significantly improved PFS and had no unexpected toxicities vs placebo-EP as first-line therapy for ES-SCLC; the HR for OS favored pembro-EP, but the significance threshold was missed. We present patient-reported outcomes (PROs) from KEYNOTE-604.

Methods

453 patients (pts) were randomized 1:1 to pembro 200 mg Q3W or saline placebo for ≤35 cycles plus 4 cycles of standard-dose EP. PRO questionnaires, including the EORTC QLQ-C30 and QLQ-LC13, were administered electronically before other trial-related procedures at cycles 1-9, 11, 13, 15, and 17, treatment discontinuation, and the 30-day safety follow-up. Mean change from baseline to wk 18 in the QLQ-C30 global health status (GHS)/QoL scale and time to true deterioration (TTD) in the QLQ-C30/LC13 composite of cough, chest pain, or dyspnea were secondary study end points; TTD in the QLQ-C30 GHS/QoL scale was a protocol-specified exploratory end point. TTD was defined as time to first ≥10-point worsening from baseline with confirmation under a right-censoring rule. HRQoL was assessed in all treated pts who completed ≥1 PRO assessment (N = 439). P values are nominal and two-sided.

Results

PRO compliance was ≥89% in both arms at baseline and wk 18. Mean QLQ-C30 GHS/QoL scale score was 60.54 in the pembro-EP arm and 58.37 in the placebo-EP arm at baseline. Score improved in both arms at wk 18; the least squares mean change from baseline (95% CI) was 8.66 points (5.26-12.06) in the pembro-EP arm and 4.23 points (0.93-7.52) in the placebo-EP arm for a difference in least squares means of 4.43 points (95% CI 0.21-8.66; P = .040). Median TTD in the QLQ-C30/LC13 composite of cough, chest pain, or dyspnea was not reached (NR) for pembro-EP and was 8.7 mo for placebo-EP (HR 0.80 [95% CI 0.56-1.14]; P = .208). Median TTD in the QLQ-C30 GHS/QoL scale was NR in either arm (HR 0.78 [95% CI 0.52-1.18]; P = .238).

Conclusions

Adding pembro to EP did not decrease, and may improve, HRQoL compared with placebo-EP as first-line therapy for ES-SCLC. Along with the efficacy and safety data observed in KEYNOTE-604, PRO data support the benefit of pembro in SCLC.

Clinical trial identification

NCT03066778, originally posted on February 28, 2017.

Editorial acknowledgement

Melanie Leiby of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Legal entity responsible for the study

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Funding

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Disclosure

H.R. Kim: Honoraria (self), Speaker Bureau/Expert testimony: Ono; Honoraria (self), Speaker Bureau/Expert testimony: Roche; Speaker Bureau/Expert testimony, Research grant/Funding (institution): MSD. M.M. Awad: Advisory/Consultancy: AbbVie; Advisory/Consultancy: Achilles Therapeutics; Advisory/Consultancy: ARIAD; Advisory/Consultancy: AstraZeneca/MedImmune; Advisory/Consultancy: Blueprint Medicines; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy, Research grant/Funding (self), Research grant/Funding (institution): Bristol-Myers Squibb; Advisory/Consultancy: Clovis Oncology; Advisory/Consultancy: Foundation Medicine; Advisory/Consultancy, Research grant/Funding (institution): Genentech; Advisory/Consultancy: Gristone Oncology; Advisory/Consultancy: Hengrui Therapeutics; Advisory/Consultancy: Maverick Therapeutics; Advisory/Consultancy, Research grant/Funding (institution): Merck Sharp & Dohme Corp.; Advisory/Consultancy: Nektar; Advisory/Consultancy: Neon Therapeutics; Advisory/Consultancy: Novartis; Advisory/Consultancy: Pfizer; Advisory/Consultancy: Syndax; Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Lilly. A. Navarro: Advisory/Consultancy, Travel/Accommodation/Expenses: Boehringer Ingelheim; Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy: Roche; Speaker Bureau/Expert testimony: Oryzon Genomics; Research grant/Funding (institution): MSD. M. Gottfried: Honoraria (self), Advisory/Consultancy: Roche; Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Advisory/Consultancy: Bristol-Myers Squibb; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): MSD; Honoraria (self), Advisory/Consultancy: AstraZeneca. S. Peters: Honoraria (institution), Advisory/Consultancy: AbbVie; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): Amgen; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: AstraZeneca; Honoraria (institution), Advisory/Consultancy: Bayer; Honoraria (institution), Advisory/Consultancy: Biocartis; Honoraria (institution), Advisory/Consultancy: Bioinvent; Honoraria (institution), Advisory/Consultancy: Blueprint Medicines; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): Boehringer Ingelheim; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Bristol-Myers Squibb; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): Clovis; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: Daiichi Sankyo; Honoraria (institution), Advisory/Consultancy: Debiopharm; Honoraria (institution), Advisory/Consultancy: Eli Lilly; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): F. Hoffmann-La Roche; Honoraria (institution), Advisory/Consultancy: Foundation Medicine; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Illumina; Honoraria (institution), Advisory/Consultancy: Janssen; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: MSD; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): Merck Serono; Honoraria (institution), Advisory/Consultancy: Merrimack; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): Novartis; Honoraria (institution), Advisory/Consultancy: Pharma Mar; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): Pfizer; Honoraria (institution), Advisory/Consultancy: Regeneron; Honoraria (institution), Advisory/Consultancy: Sanofi; Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: Seattle Genetics; Honoraria (institution), Advisory/Consultancy: Takeda; Honoraria (institution), Advisory/Consultancy: Vaccibody; Travel/Accommodation/Expenses: Roche; Research grant/Funding (institution): Biodesix. T. Csőszi: Advisory/Consultancy: Novartis pharma SAS; Travel/Accommodation/Expenses: Roche; Research grant/Funding (institution): MSD. P.K. Cheema: Honoraria (self), Advisory/Consultancy: AstraZeneca; Honoraria (self), Advisory/Consultancy: Hoffman la Roche; Honoraria (self), Advisory/Consultancy: MSD; Honoraria (self), Advisory/Consultancy: Novartis; Honoraria (self), Advisory/Consultancy: Pfizer; Honoraria (self), Advisory/Consultancy: Takeda; Advisory/Consultancy: Amgen; Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy: EMD Serono; Advisory/Consultancy: Genomic Health. D. Rodriguez-Abreu: Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Bristol-Myers Squibb; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution), Travel/Accommodation/Expenses: MSD; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche. M. Wollner: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): MSD; Honoraria (self), Advisory/Consultancy: AstraZeneca; Honoraria (institution), Speaker Bureau/Expert testimony: Roche; Advisory/Consultancy: Takeda; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Bristol-Myers Squibb; Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Speaker Bureau/Expert testimony: Boehringer Ingelheim; Speaker Bureau/Expert testimony: Novartis. J.C-H. Yang: Honoraria (institution), Advisory/Consultancy: Boehringer Ingelheim; Honoraria (institution), Advisory/Consultancy: Novartis; Honoraria (institution), Advisory/Consultancy: AstraZeneca; Honoraria (institution), Advisory/Consultancy: Roche/Genentech; Honoraria (institution), Advisory/Consultancy: Eli Lilly; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): MSD; Honoraria (institution), Advisory/Consultancy: Merck Serono; Honoraria (institution), Advisory/Consultancy: Celgene; Honoraria (institution), Advisory/Consultancy: Bayer; Honoraria (institution), Advisory/Consultancy: Pfizer; Honoraria (institution), Advisory/Consultancy: Ono Pharmaceutical; Honoraria (institution), Advisory/Consultancy: Bristol-Myers Squibb; Honoraria (institution), Advisory/Consultancy: Yuhan; Honoraria (institution), Advisory/Consultancy: Hansoh; Honoraria (institution), Advisory/Consultancy: Blueprint Medicines; Honoraria (institution), Advisory/Consultancy: Daiichi Sankyo; Honoraria (institution), Advisory/Consultancy: Amgen; Honoraria (institution), Advisory/Consultancy: Takeda; Honoraria (institution), Advisory/Consultancy: Incyte; Advisory/Consultancy: Roche. J. Mazieres: Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Bristol-Myers Squibb; Advisory/Consultancy: Lilly/ImClone; Advisory/Consultancy, Research grant/Funding (institution): MSD; Advisory/Consultancy: Novartis; Advisory/Consultancy, Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy: Pierre Fabre; Advisory/Consultancy: Roche/Genentech; Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche. F.J. Orlandi: Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Roche/Genentech; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy, Research grant/Funding (self): Bristol-Myers Squibb; Advisory/Consultancy: Lilly; Advisory/Consultancy, Research grant/Funding (institution): MSD Oncology; Advisory/Consultancy: Novartis; Advisory/Consultancy, Research grant/Funding (self): Pfizer; Advisory/Consultancy, Research grant/Funding (self): Sanofi; Speaker Bureau/Expert testimony: AstraZeneca/Genentech; Research grant/Funding (self): AstraZeneca/MedImmune; Speaker Bureau/Expert testimony: Roche; Research grant/Funding (self): Amgen; Research grant/Funding (self): Astellas Medivation; Research grant/Funding (self): Boehringer Ingelheim; Research grant/Funding (self): Celltrion; Research grant/Funding (self): mAbxience; Research grant/Funding (self): Nektar. A. Luft: Research grant/Funding (institution): MSD. M. Gümüş: Honoraria (institution), Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Honoraria (institution): Novartis; Honoraria (institution): Bristol-Myers Squibb; Honoraria (institution), Research grant/Funding (institution): MSD; Honoraria (institution): Amgen; Honoraria (institution), Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy: Gen İlac; Advisory/Consultancy: Astellas. T. Kato: Research grant/Funding (institution): MSD. G.P. Kalemkerian: Research grant/Funding (institution): Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. Y. Luo, M.L. Santorelli, M.C. Pietanza: Shareholder/Stockholder/Stock options, Full/Part-time employment: Merck Sharp & Dohme Corp. C.M. Rudin: Advisory/Consultancy: AbbVie; Advisory/Consultancy: Amgen; Advisory/Consultancy: Ascentage Pharma; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Celgene; Advisory/Consultancy, Research grant/Funding (institution): Daiichi Sankyo; Advisory/Consultancy: Genentech/Roche; Advisory/Consultancy: Harpoon Therapeutics; Advisory/Consultancy: Loxo; Advisory/Consultancy: PharmaMar; Research grant/Funding (institution): Pfizer; Research grant/Funding (institution): Viralytics; Research grant/Funding (institution): Merck Sharp & Dohme Corp.; Advisory/Consultancy: Bicycle Therapeutics; Advisory/Consultancy: Bridge Medicines; Advisory/Consultancy: Ipsen; Research grant/Funding (institution): AbbVie/Stemcentrx.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings